Drug Profile
Research programme: Evidence-based formulation therapeutics - GlaxoSmithKline/Institute of Chemical and Engineering Sciences
Alternative Names: EBF therapeutics - GlaxoSmithKline/Institute of Chemical and Engineering Sciences; Incrementally modified drugs - GlaxSmithKline/Institute of Chemical and Engineering Sciences; Value added formulations - GlaxoSmithKline/Institute of Chemical and Engineering SciencesLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator GlaxoSmithKline; Institute of Chemical and Engineering Sciences
- Developer GSK; Institute of Chemical and Engineering Sciences
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in Singapore
- 09 Apr 2013 Early research in Undefined indication in Singapore (unspecified route)